2026. Efficacy and Safety of Dapagliflozin as Adjunct Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea. Academia Journal of Medicine. 9, 2 (Oct. 2026), 201–205. DOI:https://doi.org/10.48165/ajm.2026.9.02.34.